Cancer scientists?at the universities of 天发娱乐棋牌_天发娱乐APP-官网|下载, Leeds, Oxford, Cambridge and Queen Mary, in London have been awarded more than??2m by blood cancer charity?Bloodwise.

Coordinated by the University of 天发娱乐棋牌_天发娱乐APP-官网|下载, this unique collaborative project aims to allow doctors to rapidly determine the precise genetic signature of a patient’s lymphoma and then find drugs tailor-made to target the genetic faults driving the cancer.

Professor Peter Johnson, who is heading the project at 天发娱乐棋牌_天发娱乐APP-官网|下载, said:

“Greater understanding of how lymphoma starts and develops is already leading to the creation of new, tailored, life-saving drugs to target specific cancerous cells.? This kind of precision treatment is desperately needed to help the many patients with aggressive?lymphomas?who need something more than the current treatments.”

Lymphomas are a group of cancers of the blood, and are diagnosed in over 11,000 people of all ages each year in the UK. Lymphomas start in the body’s lymphatic system, a part of our immune system that fights against disease and infection.

Survival rates for aggressive lymphomas affecting white blood cells known as B-cells have improved greatly over the last 20 years. But there still remain a considerable number of patients – several thousand every year in the UK alone – for whom current treatments are unsuccessful, resulting in important years of life lost.